Car-T Mesothelin Research
In search of a cure for solid organ cancers,
Cure The Future are raising funds for Australian research
as part of a Global Initiative into using Mesothelin CAR-T Cells to fight certain cancers
The SAAC Mesothelin Consortium
Sloan Kettering Memorial Centre
New York City, USA
Cure The Future are proud to be part of this Global fund-raising initiative, supporting a union of some of the best cancer specialists, researchers and facilities in the World – working together to achieve the greatest human challenge.
To find a cure for Cancer.
About this Research
Early clinical data from leading research centres around the World highlights the promise of Chimeric Antigen Receptor (CAR) T cells for the targeted treatment of cancers
such as pancreatic cancer, muscle cancer, ovarian cancer, some breast cancers and asbestos-related lung cancer.
A collaboration of international researchers agree it is the best possible promise of a cure we have seen – so they have got together to do clinical trials of this treatment. Australia’s team, led by Professor John Rasko, Asutralia’s leading Cell & Molecular Therapies specialist, will leverage the existing cell manufacturing infrastructure and expertise at the Cell & Molecular Therapies department at Royal Prince Alfred Hospital.
International collaborators will work together to develop these anti-mesothelin CAR-T cells – and initiate Phase I clinical trials to treat each of these cancer conditions.
In Australia, our initial focus will be on the treatment of advanced pancreatic cancer. This treatment option will be a first for Australian patients – and cellular immunotherapy of the type proposed here may revolutionise outcomes for patients and their families living with many types of cancer.
Our “CAR-T mesothelin” cancer immunotherapy is potentially capable of targeting pancreatic, ovarian, synovial and mesothelioma (a subset of lung cancer caused by exposure to asbestos) and well as other lung cancer & breast cancer subsets.